Related Experiment Video

Updated: Apr 14, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.1K

The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma

Hon-Kit Andus Wong1, Rachid El Fatimy1, Courtney Onodera2

  • 1Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 24, 2015
PubMed

Insights

Targeting specific microRNAs (miRNAs) like miR-148a and miR-31 can inhibit glioblastoma growth. This study shows uncomplexed antagomirs effectively reduce tumor progression and improve survival in mouse models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
  • MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
  • Identifying novel therapeutic targets for GBM is a significant unmet need.

Purpose of the Study:

  • To identify microRNAs associated with glioblastoma survival using The Cancer Genome Atlas (TCGA) data.
  • To investigate the role of specific microRNAs (miR-148a and miR-31) in glioma growth and progression.
  • To evaluate the therapeutic potential of inhibiting these microRNAs in preclinical GBM models.

Main Methods:

  • In silico analysis of TCGA data to identify survival-associated miRNAs.
  • Development and testing of uncomplexed antagomirs targeting miR-148a and miR-31.
  • Orthotopic xenograft glioblastoma mouse models to assess tumor growth inhibition and survival.
  • Analysis of tumor proliferation, stem cell populations, vasculature, and relevant signaling pathways (FIH1, HIF1α, Notch).

Main Results:

  • Inhibition of miR-148a and miR-31 significantly suppressed glioblastoma tumor growth and prolonged survival in mouse models.
  • Uncomplexed antagomirs targeting miR-148a and miR-31 led to reduced tumor cell proliferation, depletion of cancer stem cells, and normalized tumor vasculature.
  • The growth-promoting effects of these miRNAs were partly mediated by targeting factor inhibiting hypoxia-inducible factor 1 (FIH1) and influencing HIF1α and Notch signaling pathways.
  • Demonstrated successful intratumoral uptake and therapeutic efficacy of uncomplexed antagomirs in orthotopic glioma models.

Conclusions:

  • miR-148a and miR-31 are critical regulators of glioma growth, maintaining tumor stemness and promoting angiogenesis.
  • Inhibiting miR-148a and miR-31 with uncomplexed antagomirs represents a promising therapeutic strategy for glioblastoma.
  • This study highlights the potential of uncomplexed antagomirs for direct intratumoral delivery and treatment of brain tumors.

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.1K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.8K